Last reviewed · How we verify
Switch from tenofovir to abacavir
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of HIV.
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of HIV. Used for Treatment of HIV-1 infection in combination with other antiretroviral agents.
At a glance
| Generic name | Switch from tenofovir to abacavir |
|---|---|
| Also known as | Abacavir |
| Sponsor | Germans Trias i Pujol Hospital |
| Drug class | NRTI |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Abacavir is a prodrug that is converted into its active form, carbovir, which then inhibits the reverse transcriptase enzyme, a crucial component of the HIV replication cycle. This inhibition prevents the virus from replicating and reduces the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in combination with other antiretroviral agents
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection (PHASE2)
- Contribution of Dolutegravir to Obesity and Cardiovascular Disease (PHASE4)
- Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
- A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (PHASE4)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Switch from tenofovir to abacavir CI brief — competitive landscape report
- Switch from tenofovir to abacavir updates RSS · CI watch RSS
- Germans Trias i Pujol Hospital portfolio CI